Publikasi Scopus 2024 per tanggal 30 Juni 2024 (499 artikel)

Putera I.; Ten Berge J.C.E.M.; Thiadens A.A.H.J.; Dik W.A.; Agrawal R.; Van Hagen P.M.; La Distia Nora R.; Rombach S.M.
Putera, Ikhwanuliman (56485949000); Ten Berge, Josianne C. E. M. (56601233400); Thiadens, Alberta A. H. J. (26667331700); Dik, Willem A. (6603280038); Agrawal, Rupesh (7201475180); Van Hagen, P. Martin (57210765646); La Distia Nora, Rina (56001881000); Rombach, Saskia M. (58860662800)
56485949000; 56601233400; 26667331700; 6603280038; 7201475180; 57210765646; 56001881000; 58860662800
Relapse in ocular tuberculosis: relapse rate, risk factors and clinical management in a non-endemic country
2024
British Journal of Ophthalmology
325207
0
Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore; National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital Nhs Foundation Trust, London, United Kingdom; Lee Kong Chian School of Medicine, Nanyang Technological University of Singapore, Singapore, Singapore; Duke Nus Medical School, Singapore, Singapore
Putera I., Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands, Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands, Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Ten Berge J.C.E.M., Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands; Thiadens A.A.H.J., Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, Netherlands; Dik W.A., Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Agrawal R., National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore, National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital Nhs Foundation Trust, London, United Kingdom, Lee Kong Chian School of Medicine, Nanyang Technological University of Singapore, Singapore, Singapore, Duke Nus Medical School, Singapore, Singapore; Van Hagen P.M., Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands, Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; La Distia Nora R., Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands; Rombach S.M., Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands
Aims: To assess the risk of uveitis relapse in ocular tuberculosis (OTB) following clinical inactivity, to analyse clinical factors associated with relapses and to describe the management strategies for relapses. Methods: A retrospective study was conducted on a 10-year patient registry of patients with OTB diagnosed at Erasmus MC in Rotterdam, The Netherlands. Time-to-relapse of uveitis was evaluated with Kaplan-Meier curve and risk factors for relapses were analysed. Results: 93 OTB cases were identified, of which 75 patients achieved clinical inactivity following treatment. The median time to achieve uveitis inactivity was 3.97 months. During a median follow-up of 20.7 months (Q1-Q3: 5.2-81.2) after clinical inactivity, uveitis relapse occurred in 25 of these 75 patients (33.3%). Patients who were considered poor treatment responders for their initial uveitis episode had a significantly higher risk of relapse after achieving clinical inactivity than good responders (adjusted HR=3.84, 95% CI: 1.28 to 11.51). 13 of the 25 relapsed patients experienced multiple uveitis relapse episodes, accounting for 78 eye-relapse episodes during the entire observation period. Over half (46 out of 78, 59.0%) of these episodes were anterior uveitis. A significant number of uveitis relapse episodes (31 episodes, 39.7%) were effectively managed with topical corticosteroids. Conclusions: Our results suggest that approximately one-third of patients with OTB will experience relapse after achieving clinical inactivity. The initial disease course and poor response to treatment predict the likelihood of relapse in the long-term follow-up. Topical corticosteroids were particularly effective in relapse presenting as anterior uveitis. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Infection; Inflammation; Prognosis; Risk Factors; Treatment Medical
Lembaga Pengelola Dana Pendidikan, LPDP, (0004535/MED/D/19/lpdp2021)
IP is supported by Indonesia Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan\u2014LPDP, No: 0004535/MED/D/19/lpdp2021). The funding source had no involvement in the collection, analysis, interpretation, writing of the report and the decision to submit the article for publication.
BMJ Publishing Group
00071161
38609164
Article
Q1
1733
1668